Am J Hematol

1. JEN WY, Loghavi S, Bazinet A, Bataller A, et al
   Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies.
   Am J Hematol. 2025 Aug 28. doi: 10.1002/ajh.70046.
   

   >> Share

   
   
2. GOULART H, Jabbour E, Short N, Jain N, et al
   Contemporary Outcomes of Adults With Acute Lymphoblastic Leukemia With KMT2A Rearrangements Treated With Immunotherapy-Based Regimens.
   Am J Hematol. 2025 Aug 27. doi: 10.1002/ajh.70048.
   

   >> Share

   
   

   
   Ann Hematol

3. LAZZAROTTO D, Testi AM, Fanin M, Mosna F, et al
   Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group.
   Ann Hematol. 2025 Aug 27. doi: 10.1007/s00277-025-06550.
   

   >> Share

   
   
4. RAJENDRA KURUP A, Malcolmson J, Villani A, Kim RH, et al
   Rare germline ETV6 variant associated with thrombocytopenia and acute leukemia.
   Ann Hematol. 2025 Aug 27. doi: 10.1007/s00277-025-06536.
   

   >> Share

   
   

   
   Blood

5. CRISPINO JD
   Meddling with METTL3 in acute megakaryoblastic leukemia.
   Blood. 2025;146:1035-1036.
   

   >> Share

   
   
6. GEYER MB, DeWolf S, Mi X, Weis K, et al
   CD371-Targeted CAR T cells Secreting Interleukin-18 Exhibit Robust Expansion and Clear Refractory Acute Myeloid Leukemia.
   Blood. 2025 Aug 27:blood.2025029532. doi: 10.1182/blood.2025029532.
   

   >> Share

   
   
7. O'BRIEN C, Nursimulu N, Tyagi A, Culp-Hill R, et al
   Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemia.
   Blood. 2025 Aug 26:blood.2025029132. doi: 10.1182/blood.2025029132.
   

   >> Share

   
   

   
   Br J Haematol

8. NACHTKAMP K, Schulz F, Gattermann N, Germing U, et al
   Clinical management of CMML-State of the art.
   Br J Haematol. 2025;207:350-364.
   

   >> Share

   
   
9. SAVONA MR, Odenike O, Roboz GJ, Amin H, et al
   Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies.
   Br J Haematol. 2025;207:432-444.
   

   >> Share

   
   
10. KONUMA T, Shimomura Y, Mizuno S, Yamasaki S, et al
    Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013-2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantat
    Br J Haematol. 2025;207:484-497.
    

    >> Share

    
    
11. XIAO J, Xia Y, Yin F, Shi Z, et al
    Global spatiotemporal distribution characteristics and regional risk stratification model of acute myeloid leukaemia based on molecular genetics and cytogenetic features.
    Br J Haematol. 2025;207:395-406.
    

    >> Share

    
    

    
    Cancer

12. KAO HW, Chang H, Kuo MC, Wu JH, et al
    Genetic evolution of myeloproliferative neoplasms from chronic phase to blastic phase: An analysis of 46 paired samples.
    Cancer. 2025;131:e70048.
    

    >> Share

    
    

    
    Cancer Res

13. SU Y, Li S, Wang L, Wang Y, et al
    Loss of SETD8 Impairs Mitochondrial Homeostasis to Suppress Leukemia Stem Cell Function in t(8;21) Acute Myeloid Leukemia.
    Cancer Res. 2025 Aug 29. doi: 10.1158/0008-5472.CAN-24-3659.
    

    >> Share

    
    

    
    Int J Hematol

14. ONO K, Horiguchi H, Iyama S, Sato K, et al
    Neuropeptide TIP39 induces autophagy in PTH2 receptor-positive myeloid neoplasms.
    Int J Hematol. 2025;122:400-412.
    

    >> Share

    
    

    
    Leukemia

15. CURIK N, Laznicka A, Krizkova J, Suchankova P, et al
    Venetoclax in combination with ponatinib for the treatment of asciminib-resistant chronic myeloid leukemia.
    Leukemia. 2025 Aug 26. doi: 10.1038/s41375-025-02732.
    

    >> Share

    
    
16. HLEIHEL R, Skayneh H, Wu HC, Hamie M, et al
    Retinoic acid disrupts an NPM1c/ROS/SENP3/ARF oncogenic axis in acute myeloid leukemia.
    Leukemia. 2025 Aug 26. doi: 10.1038/s41375-025-02731.
    

    >> Share

    
    
17. RONNACKER J, Muller PJ, Mikesch JH, Zukunft S, et al
    Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis.
    Leukemia. 2025;39:2174-2180.
    

    >> Share

    
    
18. BERTOLI R, Cao D, Tuckey O, Gammell S, et al
    5-Azacytidine and decitabine induce C > G transversions in both murine and human cells.
    Leukemia. 2025;39:2112-2124.
    

    >> Share

    
    
19. VICK EJ, Hassan A, Choi K, Bennett J, et al
    Targeting of IRAK4 and GSPT1 enhances therapeutic efficacy in AML via c-Myc destabilization.
    Leukemia. 2025;39:2163-2173.
    

    >> Share

    
    
20. CALDERON AS, Ghazanfari R, Masoumi Z, Kharazi S, et al
    Ontogeny-specific induction of the KMT2A::AFF1-fusion drives development of a distinct CD24 positive pre-leukemic state.
    Leukemia. 2025;39:2099-2111.
    

    >> Share

    
    
21. NADEU F, Shuai S, Clot G, Hilton LK, et al
    Disease-specific U1 spliceosomal RNA mutations in mature B-cell neoplasms.
    Leukemia. 2025;39:2076-2086.
    

    >> Share

    
    

    
    PLoS One

22. SAMI KHAFAGA D, El-Kenawy EM, Rizk FH, Eid MM, et al
    Ocotillo optimization-driven deep learning for bone marrow cytology classification.
    PLoS One. 2025;20:e0330228.
    

    >> Share

    
    
23. NAVAKANITWORAKUL R, Saelue P, Penglong T, Molika P, et al
    Exosomal miRNA expression profiling in patients with imatinib resistant Chronic myeloid leukemia: A pilot study.
    PLoS One. 2025;20:e0331479.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share